3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
4
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Leukemia, Myelomonocytic, Chronic
1
Kidney Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Sunitinib
19
Everolimus
17
Bevacizumab
13
aldesleukin
11
Sorafenib
11
Interleukin-2
10
Cyclophosphamide
10
Axitinib
10
Nivolumab
9
fludarabine phosphate
7
fludarabine
7
pembrolizumab
5
Gemcitabine
5
temsirolimus
4
pazopanib
4
Ipilimumab
4
peginterferon alfa-2b
3
durvalumab
3
cabozantinib
3
Radiosurgery
3
Interferon-alpha
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Filgrastim
3
Erlotinib Hydrochloride
3
Cryosurgery
3
vandetanib
2
spartalizumab
2
perflutren
2
ixabepilone
2
chiron
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Kidney Neoplasms
×
CB-839
×
Clear all
NCT03428217
2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2
Completed
444 enrolled
15 charts